Notice about cookies

Close

This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy. By clicking Accept below or continuing to use this website (including closing this message), you confirm that you have read and consent to our use of cookies as detailed in our Cookie Policy.

Accept

UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Sep

11

UCB PharmD Second-Year Fellows Share Reflections and Advice

Read More Share:linkedin| twitter| email

Sep

05

Announcing the 2023 UCB Family Epilepsy Scholarship Winners

Read More Share:linkedin| twitter| email

Aug

28

Breaking Down the Value Chain: Patient Voices Advocating for Change

Read More Share:linkedin| twitter| email

Aug

03

Employee Spotlight: David Hornbaker’s Heart for Helping Patients

Read More Share:linkedin| twitter| email

Aug

01

Evolving Expectations for Dermatological Conditions

Read More Share:linkedin| twitter| email

Jul

21

UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive

Read More Share:linkedin| twitter| email

Jun

27

Fulfilling Our Ambition to Deliver an FDA-Approved Treatment for People Living with Generalized Myasthenia Gravis

Read More Share:linkedin| twitter| email

Jun

27

UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

Read More Share:linkedin| twitter| email

Jun

14

How UCB Is Supporting the Mental Health of Patients and Caregivers

Read More Share:linkedin| twitter| email

Jun

14

Recognizing Ethical Leadership at UCB

Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)